Here’s our weekly round-up of what illnesses are spreading the most in Metro Detroit communities, according to our local ...

The two studies — OBERON and TITANIA — evaluated the drug against placebo in adults with symptomatic COPD who had a history of at least two moderate or at least one severe COPD exacerbations (or ...

The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...

Lunsekimig is one of a trio of clinical candidates that Sanofi is developing as successors to its big-selling IL-3 and IL-13 ...

Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, ...

Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.” ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...

Going from a medium-dose inhaled corticosteroid to a biologic for asthma led to significant decreases in exacerbations, ...